In Situ Vaccination Using Unique TLR9 Ligand K3-SPG Induces Long-Lasting Systemic Immune Response and Synergizes with Systemic and Local Immunotherapy

K3-SPG, a second-generation nanoparticulate Toll-like receptor 9 (TLR9) ligand consisting of K-type CpG oligodeoxynucleotide (ODN) wrapped with schizophyllan, integrated the best of conventional CpG ODNs, making it an ideal cancer immunotherapy adjuvant.